Drugs / MDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01011777 | Feb 2017 → Jan 2020 | bladder exstrophy, urethral intrinsic sphincter deficiency | Johns Hopkins University | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01011777 ↗ |
| Modality | Cell therapy | “muscle derived cell (MDC) therapy” NCT01011777 ↗ |
| Route | Other | “MDC product will be endoscopically injected” NCT01011777 ↗ |